Literature DB >> 14967142

Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

Si Qing Zhang1, Wentian Yang, Maria I Kontaridis, Trever G Bivona, Gengyun Wen, Toshiyuki Araki, Jincai Luo, Julie A Thompson, Burkhart L Schraven, Mark R Philips, Benjamin G Neel.   

Abstract

The protein-tyrosine phosphatase Shp2 plays an essential role in growth factor and integrin signaling, and Shp2 mutations cause developmental defects and/or malignancy. Previous work has placed Shp2 upstream of Ras. However, the mechanism of Shp2 action and its substrate(s) are poorly defined. Additional Shp2 functions downstream of, or parallel to, Ras/Erk activation also are proposed. Here, we show that Shp2 promotes Src family kinase (SFK) activation by regulating the phosphorylation of the Csk regulator PAG/Cbp, thereby controlling Csk access to SFKs. In Shp2-deficient cells, SFK inhibitory C-terminal tyrosines are hyperphosphorylated, and the tyrosyl phosphorylation of multiple SFK substrates, including Plcgamma1, is decreased. Decreased Plcgamma1 phosphorylation leads to defective Ras activation on endomembranes, and may help account for impaired Erk activation in Shp2-deficient cells. Decreased phosphorylation/activation of other SFK substrates may explain additional consequences of Shp2 deficiency, including altered cell spreading, stress fibers, focal adhesions, and motility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967142     DOI: 10.1016/s1097-2765(04)00050-4

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  171 in total

1.  G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase.

Authors:  Muneyoshi Futami; Quan-Sheng Zhu; Zakary L Whichard; Ling Xia; Yuehai Ke; Benjamin G Neel; Gen-Sheng Feng; Seth J Corey
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.

Authors:  Murielle Glondu-Lassis; Mathilde Dromard; Magali Lacroix-Triki; Philippe Nirdé; Carole Puech; Dora Knani; Dany Chalbos; Gilles Freiss
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 4.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

5.  Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.

Authors:  Maike Krenz; Katherine E Yutzey; Jeffrey Robbins
Journal:  Circ Res       Date:  2005-09-15       Impact factor: 17.367

Review 6.  Control of MAP kinase signaling to the nucleus.

Authors:  Kunio Kondoh; Satoru Torii; Eisuke Nishida
Journal:  Chromosoma       Date:  2005-05-18       Impact factor: 4.316

7.  Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth.

Authors:  Elisa Giannoni; Francesca Buricchi; Giovanni Raugei; Giampietro Ramponi; Paola Chiarugi
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

8.  The Protein Tyrosine Phosphatase Shp2 Regulates Oligodendrocyte Differentiation and Early Myelination and Contributes to Timely Remyelination.

Authors:  Jared T Ahrendsen; Danielle E Harlow; Lisbet T Finseth; Jennifer N Bourne; Sean P Hickey; Elizabeth A Gould; Cecilia M Culp; Wendy B Macklin
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

9.  S-nitrosylated SHP-2 contributes to NMDA receptor-mediated excitotoxicity in acute ischemic stroke.

Authors:  Zhong-Qing Shi; Carmen R Sunico; Scott R McKercher; Jiankun Cui; Gen-Sheng Feng; Tomohiro Nakamura; Stuart A Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

10.  HIF-1α Dependent Wound Healing Angiogenesis In Vivo Can Be Controlled by Site-Specific Lentiviral Magnetic Targeting of SHP-2.

Authors:  Yvonn Heun; Kristin Pogoda; Martina Anton; Joachim Pircher; Alexander Pfeifer; Markus Woernle; Andrea Ribeiro; Petra Kameritsch; Olga Mykhaylyk; Christian Plank; Florian Kroetz; Ulrich Pohl; Hanna Mannell
Journal:  Mol Ther       Date:  2017-04-20       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.